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Edited by Sandro SonninoAbstract Elongation of very long-chain fatty acids (ELOVL)
members were overexpressed in two preadipocyte cell lines,
ELOVL2 and ELOVL3 in 3T3-L1 cells, and ELOVL1–3 in
F442A cells. Cells overexpressing ELOVL2, whose preferred
substrates are arachidonic acid (AA, C20:4n6) and eicosapen-
taenoic acid (EPA, C20:5n3), showed an enhanced triacylglyc-
erol (TAG) synthesis and subsequent accumulation of lipid
droplets. Incorporation of fatty acid (FA) but not of glucose into
TAG was enhanced by ELOVL2-overexpression. Two lipogenic
genes encoding diacylglycerol acyltransferase-2 (DGAT2) and
fatty acid-binding protein-4 (FABP4, aP2) were induced in
ELOVL2-overexpressing cells, whereas no such eﬀect was seen
on the fatty acid synthase (FAS) gene.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Fatty acids (FAs), which are exogenously incorporated or
endogenously synthesized/elongated and their CoA esters are
essential molecules in cells, e.g. as a fuel for energy production,
as membrane components, as signaling molecules, and as reg-
ulators of various transcriptional factors. In mammals, de novo
FA synthesis up to palmitic acid (C16:0) is carried out in the
cytosol by fatty acid synthase (FAS). Further FA-elongation
activity making long chain- and very long chain-fatty acids
(VLCFAs; PC18) resides in the endoplasmic reticulumAbbreviations: AA, arachidonic acid (C20:4n6); BSA, bovine serum
albumin; DEX, dexamethasone; DHA, docosahexaenoic acid (D-
4,7,10,13,16,19-C22:6n3); DMEM, Dulbecco’s modiﬁed Eagle’s
medium; DGAT, diacylglycerol acyltransferase; ELOVL, elongation
of very long-chain fatty acids; EPA, eicosapentaenoic acid (D-
5,8,11,14,17-C20:5n3); FA, fatty acid; FABP, fatty acid-binding
protein; FAS, fatty acid synthase; IBMX, 3-isobutyl-1-methyl-xan-
thine; Oil-Red-O, [1-(p-xyrylazoxyrylazo)-2-naphthol]; PPAR, perox-
isome proliferator-activated receptor; PUFA, polyunsaturated fatty
acid; RT, reverse transcriptase; RXR, retinoid X receptor; SREBP,
sterol regulatory element-binding protein; TAG, triacylglycerol;
VLCFA, very long-chain fatty acid
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doi:10.1016/j.febslet.2007.05.081(ER), peroxisomes [1,2], and in mitochondria [3]. In the ER,
a family of enzymes, elongation of very long-chain fatty acids
(ELOVL; gene name Elovl), catalyze the ﬁrst rate-limiting con-
densation step of the sequential VLCFA synthesis reaction
[4,5].
Seven ELOVL members have been identiﬁed in mice and hu-
mans, each having a respective gene locus, a unique tissue spe-
ciﬁc expression pattern with overlapping substrate speciﬁcity
[5–8]. Saturated and monounsaturated FAs are preferred sub-
strates of ELOVL1, ELOVL3 and ELOVL6 [8–11], whereas
ELOVL2, ELOVL4 and ELOVL5 use polyunsaturated fatty
acids (PUFAs) primarily [10,12,13].
Saturated FA biosynthesis uses only FAS and ELOVL,
whereas monounsaturated FA synthesis requires an additional
desaturation reaction either by D9- or D6-desaturase [14,15].
Multiple reactions are included in PUFA synthesis pathways
such as elongations (by ELOVL2, 4 and 5) and desaturations
(by D5- and D6-desaturase), in that the existence of primer sub-
strates such as linoleic acid (C18:2n6) and a-linolenic acid
(C18:3n3) is a prerequisite (essential FAs). Furthermore,
one round of peroxisomal b-oxidation is required in mammals
to obtain docosahexaenoic acid (DHA, C22:6n6) and
C22:5n6 [16]. Because vertebrates lack x3(n3) desaturase,
n3 and n6 PUFA synthesis pathways are not interchange-
able [15].
Both n6 and n3 PUFAs are a component of phospholipid
thus inﬂuence the structure and function of the membrane [17].
The membrane of the adipose tissue, liver, muscle and the kid-
ney is rich in n6 PUFAs, whereas that of the brain, testis and
of retina contain n3 PUFAs predominantly [18].
The n6 to n3 ratio aﬀects the production of an eicosanoid.
An n6 PUFA, arachidonic acid (AA, C20:4n6) is the precur-
sor of the highly inﬂammatory prostaglandin E2, whereas n3
PUFAs such as eicosapentaenoic acid (EPA, C20:5n3) be-
come the low inﬂammatory prostaglandin E3 [19]. In the liver,
n3 PUFAs are known to catabolize FA by functioning as li-
gands for PPAR-a [20]. Despite the extensive knowledge on
other enzymes, few reports are available as to the function of
ELOVL members in PUFA synthesis pathways. The present
study shows the ﬁrst evidence that overexpression of a PUFA
elongase ELOVL2 in preadipocytes enhances triacylglycerol
(TAG) synthesis and accumulation of fat droplets.2. Materials and methods
2.1. Buﬀer solutions
The following buﬀer solutions were used. Elongation assay buﬀer;
50 mM sodium phosphate, 50 lM fatty acyl-CoA (Sigma or Avanti),blished by Elsevier B.V. All rights reserved.
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albumin (BSA, Roche) (pH 6.8): RNA extraction solution; 38% (v/v)
phenol, 0.8 M guanidium thiocyanate, 0.4 M ammonium thiocyanate,
0.1 M sodium acetate and 5% (v/v) glycerol: Hybridization solution; 5·
NaCl/Cit, 50 mM sodium phosphate (pH 7.0), 7% (v/v) sodium dode-
cyl sulfate, 50% (v/v) formamide and 2% (w/v) Blocking reagent
(Roche): lipid extraction solution; 66% (v/v) chloroform, 34% (v/v)
methanol and 0.5 mM (w/v) butylated hydroxy toluene: FA labeling
medium; Dulbecco’s modiﬁed Eagle’s medium (DMEM) (5.5 mM glu-
cose), 250 lM palmitic acid, 0.1 lCi/ml [U-14C] palmitic acid (Amer-
sham) and 25 lM FA-free bovine serum albumin.2.2. Cell culture and in vitro diﬀerentiation
3T3-L1, F442A, and NIH3T3 cells were obtained from the European
Collection of Cell Cultures consortium. Dulbecco’s modiﬁed Eagle’s
medium (DMEM, 25 mM glucose) supplemented with 10% (v/v) bovine
calf serum iron-fortiﬁed (SAFC Biosciences), streptomycin (100 lg/ml)
and penicillin (100 U/ml) was used as amedium. For diﬀerentiation, two
days after conﬂuence, cells were incubated with a diﬀerentiation med-
ium containing DMEM (25 mM glucose), 10% (v/v) fetal bovine serum,
antibiotics, 1 lM insulin, 1 lM dexamethasone (DEX), and 500 lM
3-isobutyl-1-methyl-xanthine (IBMX). After 48 h, cells were treated
with the diﬀerentiation medium without IBMX and DEX. This
was renewed every second day and continued until the end of each
experiment.2.3. Construction and creation of ELOVLs-expressing cells
The XhoI-cloning site of a mammalian expression vector pCXN2
[21] was converted to a NotI-site and used for Elovl-expression units.
For Elovl1 and Elovl3, an NheI-site in the reported constructs [5,22]
was modiﬁed to the NotI-site, and each cDNA ﬂanked by two NotI-
sites isolated by NotI. For Elovl2, a cDNA in pEMR1023 [8] was ex-
cised by SalI and BglII, and both ends converted to NotI-sites. The
Elovl1–3 cDNA fragments obtained were ligated to modiﬁed pCXN2
as above. These constructs were introduced into 3T3-L1 and F442A
cells using a calcium phosphate coprecipitation method, then stably-
transfected cells selected for three weeks with 1.2 lM G418 (Invitro-
gen). Established cells were maintained in the presence of 0.3 lM
G418, without reaching conﬂuence (until 70%).2.4. RNA analysis
Total RNA was prepared from cells using RNA isolation solution,
following a procedure for TRIzol (Invitrogen). Digoxygenin-labeled
cRNA probes were prepared [23] using the following constructs as
templates. For fatty acyl-CoA binding protein-4 (FABP4; aP2), a
cDNA prepared by reverse transcriptase (RT)-PCR (see Supplemen-
tary Table 1 for primers) was ligated to pGemT (Promega). For Elovl1
and Elovl3, constructs in pCIneo [5,21] were used. For Elovl2, a cDNA
in pEMR1023 [8] was subcloned into pGemT. For diacylglycerol acyl
transferase (DGAT)2 and fatty acid synthase (FAS), two expressed se-
quence tag clones (IMAGE5123807 and IMAGE4195432) were used.
Northern hybridization was carried out using hybridization solution
and probes, and the hybrid detected [23]. Results were recorded with
a CCD-camera; LAS1000 (Fuji).
For RT-PCR, cDNA was synthesized from total RNA (2 lg) using
MMLV-RT (Invitrogen) and an oligo-dT primer. PCR was performed
as follows; 92 C for 1 min, 55 C for 1 min and 72 C for 1 min. At the
completion of 30, 33, 36, and 39 cycles, a portion of the product (10 ll)
was separated on a 1.2% agarose gel.2.5. Preparation of microsomes and FA elongation assay
Microsomes were prepared from cells as described [24]. FA elonga-
tion assay was carried out as follows. Microsomes (40 lg/assay) were
pre-incubated for 3 min at 37 C in elongation assay buﬀer and assays
(200 ll/assay) initiated by adding malonyl-CoA (50 lM, with 3 dpm/
pmol of [2-14C] malonyl-CoA; Hartman Analytic). Reactions were per-
formed within the range of linearity (up to 60 min). At each time point,
reactions were terminated with 2.5 M potassium hydroxide in 20% (v/
v) methanol (200 ll), followed by saponiﬁcation for 60 min at 65 C,
then the products acidiﬁed by adding 6 N hydrochloric acid in 50%
(v/v) methanol (200 ll). The free-FA released was recovered by three
extractions with hexane (each 1 ml), and upper-phases were mixed withliquid scintillation ﬂuid (each 5 ml) (Perkin Elmer), followed by scintil-
lation counting (LS-6500, Beckman).
2.6. Lipid analysis
Cells were ﬁxed for 15 min with a 3.7% (w/v) paraformaldehyde
solution in PBS, stained for 30 min with 2.5 mM Oil-Red-O [1-(p-
xyrylazoxyrylazo)-2-naphthol] in 50% (v/v) 2-propanol. Following
two 10 min washings with 50% (v/v) 2-propanol, photographs were
taken with LAS1000.
To analyze the incorporation of FA into TAG, cells grown in 6-well
plates were incubated for 16 h in DMEM (5.5 mM glucose) without
serum. Following two washings with 30 lM BSA (FA-free) in PBS,
cells were incubated with FA labeling medium (2 ml/well). For glucose
incorporation, the medium containing [U-14C] glucose was used in-
stead of [U-14C] palmitic acid.
Total lipid was extracted as follows; cells resuspended in PBS (1 ml/
well) were subjected to sonication (twice each for 10 s), and a portion
of the lysate (100 ll) was used for determination of protein concentra-
tion [23]. The remaining 900 ll was mixed with lipid extraction solu-
tion (3.6 ml, twice each for 15 s) followed by centrifugation at
1000 · g for 5 min. The separated lower phase was dried in a vacuum
oven and dissolved in lipid extraction solution. Lipid equivalent to
500 lg of protein was separated on a TLC plate (silica gel 60, Merck)
[25], and 14C-labeled lipid was detected using a phosphorimager
(BAS3000, Fuji). All lipids were visualized by spraying of the plate
with 500 mM copper sulphate in 50% (v/v) methanol followed by bak-
ing at 150 C for 20 min, then the image was recorded with LAS1000.
The location of individual lipid species was veriﬁed using lipid stan-
dards (Sigma).2.7. Data analysis
Results of Northern blotting and TLC were analyzed using pro-
grams, NIH image (NIH, USA) or Image gauge (Fuji). For statistics,
one-way repeated-measures ANOVA and Tukey’s post hoc test for
multiple comparisons were used (Prism, Graphpad software); **,
P < 0.001; *, P < 0.05.3. Results
3.1. Functional expression of ELOVLs
To evaluate how respective ELOVL members aﬀect cellular
lipid metabolism, we created cell lines stably expressing
ELOVL2 and ELOVL3 in 3T3-L1 cells, and ELOVL1–3 in
F442A cells (Fig. 1). These two preadipocytes retain a potency
to diﬀerentiate into adipocytes and are thus used to study cel-
lular lipid metabolism [26].
Endogenous Elovl1–3 mRNAs were not detectable by
Northern blotting in all the cells examined, therefore semi-
quantitative RT-PCR was applied. In all cells, although the
amount was low, Elovl2 and Elovl3 mRNAs were detectable,
whereas a certain amount of Elovl1 mRNA was observed
(Fig. 1A). The order of endogenous Elovl1–3 mRNA levels
estimated was Elovl 1> Elovl 2@ Elovl 3. In stably-transfected
cells, Elovl mRNAs were detected by Northern blotting with
the predicted length (1.4 kbp) (Fig. 1B). Using microsomes
prepared from ELOVL2- and ELOVL3-expressing cells, FA-
elongation activity was analyzed (Fig. 1C). With palmitoyl-
CoA (C16:0-CoA), a substantial elongation activity was seen
in vector-transfected 3T3-L1 cells (170 pmol/min/mg). There
was no increased activity in ELOVLs-expressing cells. Rather,
ELOVL2-expressing cells showed a diminished activity
(Fig. 1C). The vector-transfected F442A cells had a lower pal-
mitoyl-CoA elongation activity than 3T3-L1 cells (Fig. 1C and
D). Increased palmitoyl-CoA elongation activity was seen in
F442A cells expressing ELOVL2 and ELOVL3, conﬁrming
the functional expression of ELOVLs (Fig. 1D).
Fig. 1. Functional expression of ELOVLs in preadipocytes. (A) Endogenous Elovl1–3 mRNAs in 3T3-L1, F442A and parental NIH-3T3 cells
detected by semi-quantitative RT-PCR. cDNAs were standardized for b-actin. (B) Elovl1–3 transcripts in stably transfected 3T3-L1 cells analyzed by
Northern blotting. Arrows show positions of Elovl mRNAs (1.4 kbp). Mixed probes (Elovl1–3) were used. Data shown are combined photographs
from diﬀerent time exposures of the membrane. (C,D) FA elongation activity in microsomes from ELOVL2- and ELOVL3-expressing cells. (C) 3T3-
L1-derived cells microsomes. (D) F442A-derived cells microsomes. Error bars represent the means ± S.D. of three diﬀerent time points measured in
duplicate; **, P < 0.001.
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F442A-derived cells, elongation activity was signiﬁcantly in-
creased by ELOVL2-overexpression (Fig. 1C).3.2. ELOVL2 enhances accumulation of lipid droplets
Oil-Red-O staining showed a pronounced accumulation of
lipid droplets in ELOVL2-expressing cells (Fig. 2A). In 3T3-
L1 cells, diﬀerentiation was low in vector-transfected cells,
however lipid accumulation was obvious in ELOVL2-express-
ing cells (Fig. 2A). In contrast, all F442A-derived cells diﬀeren-
tiated moderately, in that ELOVL2-expressing cells
nevertheless showed the highest accumulation of lipid drop-
lets (Fig. 2A) and the TAG content (Fig. 2B and C). This
enhanced TAG formation by ELOVL2 was continuous in
the late stage of diﬀerentiation (on days 8 and 10) (Fig. 2D
and E).
3.3. Utilization of FA and glucose for TAG synthesis
By adding [U-14C] palmitic acid or [U-14C] glucose into the
media, their utilization for TAG synthesis was analyzed.
ELOVL2-expressing cells incorporated [U-14C] palmitic acid
into TAG eﬃciently, both in the diﬀerentiated (Fig. 3A andC) and undiﬀerentiated (Fig. 3B and D) states. With [U-14C]
glucose, although 14C-labeled TAG was increased by time,
the amount of 14C-labeled TAG (at 10 h) was the same be-
tween the cell lines examined (Fig. 3E).3.4. Analysis of mRNA levels for adipogenic genes
Whether the increased TAG synthesis by ELOVL2-overex-
pression coupled with lipogenic gene expression, the mRNA
levels of three lipogenic genes, i.e. FABP4, FAS, and DGAT2,
were examined by Northern blotting. A large amount of
FABP4 mRNA was found in ELOVL2-expressing cells com-
pared with other cells (Fig. 4). DGAT2 mRNA was also abun-
dant in ELOVL2-expressing cells (Fig. 4). In contrast, there
was no ELOVL2-dependent increase in the FAS (fatty acid
synthase) mRNA level, but this was rather high in ELOVL3-
expressing cells (Fig. 4).4. Discussion
The present study demonstrated that excess ELOVL2 en-
hances TAG synthesis and loading of lipid in preadipocytes.
Fig. 2. ELOVL2-overexpression enhances accumulation of lipid droplets and the TAG content in 3T3-L1 and F442A cells. (A) ELOVLs-expressing
cells and their wild-type (WT) cells were diﬀerentiated for 14 days, and stained with Oil-Red-O. (B–E) F442A cells transfected with ELOVL1–3 were
diﬀerentiated for 10 days and lipid resolved by TLC. (B) Lipid samples were prepared at the late stage of diﬀerentiation (10 days) and separated by
TLC. Each lane contains total lipid equivalent to 500 lg of protein. (C) The TAG contents in (B) are shown as a percentage of ELOVL2, after
standardization for the cholesterol spot. (D) During diﬀerentiation, total lipid samples were sequentially taken (on days 0, 2, 5, 8, and 10) and
separated by TLC. (E) The relative TAG content in (D) is expressed as a percentage of the maximum value. Chol, cholesterol; Chol E, cholesterol
ester.
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nounced in 3T3-L1 cells, however this led us to identify the ef-
fect of ELOVL2-overexpression in preadipocytes by simple
Oil-Red-O staining (Fig. 2).
The mouse Elovl2 cDNA was identiﬁed [8], by a homology
search with ELOVL3, whose mRNA in brown adipose tissue
greatly increases by cold exposure [22,27,28]. An abundant
amount of Elovl2 mRNA in testis suggested that ELOVL2
elongates PUFAs [8]. This was subsequently demonstrated in
mouse [10], human [29] and rat [30,31] orthologs, and in this
study (Fig. 1C). The reduced palmitoyl-CoA elongation activ-
ity appeared in ELOVL2-expressing 3T3-L1 cells (Fig. 1C)
might be the result of a compensational reduction of endoge-
nous ELOVL(s) (e.g. ELOVL1).
Lipogenic pathways for TAG synthesis are transcriptionally
regulated by sterol regulatory element-binding protein(SREBP)-1c and peroxisome proliferator-activated receptor
(PPAR)-c, where various PUFAs are known to regulate the
function of these transcriptional factors [20,32,33]. We exam-
ined the expression levels of these target genes in established
cell lines.
PUFA is known to inhibit the function of SREBP-1c [34,35].
However, ELOVL2-overexpression had no eﬀect on an
SREBP-1c target gene, FAS (Fig. 4). Another group also sug-
gested that Elovl2 gene transcription is not regulated by
SREBP-1c in rat hepatocytes [31]. Therefore the connection
between ELOVL2 and SREBP-1c seems inconsiderable. The
reason for the high FAS gene expression in ELOVL3-express-
ing cells remains to be elucidated.
An adipose tissue-speciﬁc diﬀerentiation marker FABP4
(aP2) was induced by ELOVL2 (Fig. 4). FABP4 gene expres-
sion is regulated by PPAR-c [36]. Liver-type FABP acquires
Fig. 3. Incorporation of extra-cellular FA and glucose into TAG in ELOVLs-overexpressing 3T3-L1 cells. (A–D) Incorporation of [U-14C] palmitic
acid into TAG in ELOVLs-expressing cells was analyzed with diﬀerentiated (A,C, 10 days) and with undiﬀerentiated (B,D) conditions. (A,B)
Representative TLC results visualized on the phosphorimager. (C,D) The relative amount of 14C-labeled TAG is expressed as a percentage of the
maximum value (from two diﬀerentiation experiments measured in duplicate). DAG, diacylglycerol; FFA, free fatty acid; Chol E, cholesterol ester.
(E) [U-14C] glucose incorporation into TAG in diﬀerentiated cells. Radiolabeled TAG synthesized from glucose (glycerol-3-phosphtate) was
measured at 10 h after the addition of [U-14C] glucose. Statistical signiﬁcances were shown versus control (vector) values of corresponding time
points; **, P < 0.001; *, P < 0.05.
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into the nucleus, and transfer of ligands (FA) to PPAR-c, then
trans-activates target genes [37]. Moreover, a heterodimer
partner of PPAR-c, retinoid X receptor (RXR)-a [37], is acti-
vated by DHA (an n6 PUFA) [38].
DGAT2, a last-step enzyme in the TAG synthesis pathway,
was also induced by ELOVL2-overexpression (Fig. 4).
DGAT2 mRNA increases along with diﬀerentiation of 3T3-
L1 cells ([39] and Fig. 4). Currently, there is no evidence that
DGAT2 is under the control of SREBP-1c or PPAR-c. How-
ever at the protein level, EPA-CoA (PUFA) has been shown to
inhibit DGAT activity [40].
As to catabolic eﬀects, n3PUFAs are reported to induce
FA-oxidation through the action of PPAR-a [20]. Overexpres-
sion of a PUFA elongase ELOVL2 in cells was therefore ex-
pected to accelerate cellular catabolism. However, the
present study showed enhanced TAG synthesis, suggesting
no major correlation between catabolism and enhanced TAG
synthesis by ELOVL2.
With the time scale we analyzed (10 h), extracellular FA but
not glucose was shown as the major source of TAG, especially
in ELOVL2-expressing cells (Fig. 3A–E). Transport of FA is
one of the factors to be considered for this eﬀect. A composi-
tional change in various types of FA species such as incorpo-
rated FA and its elongated intracellular VLCFA modiﬁes themembrane ﬂuidity and thus the localization of caveolae [15].
This could aﬀect the functions of fatty acid transporter FATP1
[41] and other related transporters.5. Conclusion
How one particular ELOVL member, i.e. ELOVL2, aug-
ments TAG synthesis is not revealed, yet the present study
showed evidence supporting the ﬁnding. One hypothesis is as
follows; in ELOVL2-expressing cells, an increased amount of
elongated-PUFAs (products) or consumption of PUFAs (as
substrates) change the composition of a cellular FA (-CoA)
pool, induce PPAR-c-controlled lipogenic genes, enhance
TAG synthesis followed by accumulation of lipid droplets in
cells. Another possibility is the regulation of various enzyme
activities by PUFAs, e.g. DGAT2. It should be noted herein
that our observation was found in preadipocytes whereas
numerous catabolic eﬀects of n3 PUFAs are mainly reported
in vivo. Further mechanistic as well as more broad investiga-
tions are needed to delineate and generalize the ﬁnding pre-
sented, yet quests for speciﬁc inhibitors, inducers and
connected pathways for ELOVL2 will provide medically useful
information to control lipid metabolism.
Fig. 4. Diﬀerentiation-dependent changes in the mRNA levels of
lipogenic genes in 3T3-L1 cells expressing ELOVL2 and ELOVL3
Total RNA isolated during diﬀerentiation of 3T3-L1 cells (days 0, 2, 4,
6 and 10) was subjected to Northern blotting using FABP4, DGAT2
and FAS as probes. Each lane contains 5 lg of total RNA. RNA
photographs are shown as a reference of loading. The mRNA level was
represented as a percentage of the maximum value, after standardi-
zation with 18S RNA.
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